US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% SDEV $7.48 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00%
FinancialContent

Articles published by Zenas BioPharma

News headline image
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
News headline image
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO